Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries SciSparc Ltd. - Ordinary Shares (NQ: SPRC ) 0.2292 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about SciSparc Ltd. - Ordinary Shares < Previous 1 2 3 4 5 Next > SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment September 30, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX September 26, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment September 23, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment September 18, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy September 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer September 11, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment September 06, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment September 06, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination August 29, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million August 28, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome August 23, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board August 22, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment August 19, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million August 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Updates Regarding the Status of the AutoMax Merger August 14, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug August 06, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer July 22, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million July 17, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification July 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss July 16, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company July 08, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Secures Strategic Advantage with Grant of European Patent May 31, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc to Acquire AutoMax April 11, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression March 27, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research March 21, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Granted Another Patent, Strengthening its Core Technology in Canada March 18, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial March 14, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure March 12, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder March 08, 2024 From SciSparc Ltd Via GlobeNewswire SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe March 07, 2024 From SciSparc Ltd Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.